Meeting Banner
Abstract #1127

Longitudinal & quantitative 3D-R2* MRI validates methimazole-enhanced intranasal delivery of labeled neural stems cells for treatment of glioblastoma.

Daniele Procissi1, Nicola Bertolino2, Drew Spencer3, Dou Yu 3, Katarzyna C Pituch3, Maciej S Lesniak3, and Irina V Balyasnikova3

1Radiology & Biomedical Engineering, Northwestern University, Chicago, IL, United States, 2Radiology, Northwestern University, Chicago, IL, United States, 3Neurosurgery, Northwestern University, Chicago, IL, United States

Longitudinal and quantitative 3D-R*2 MRI provides a unique platform for tracking labeled cells in vivo, across subjects and time-points following treatment. In this study we use this approach to demonstrate how FDA approved methimazole can enhance intranasal delivery and accumulation of labeled and therapeutically enhanced neural stem cells in glioma xenografts. 3D rendering of the high resolution quantitative maps across different sessions enhances visualization of the NSC accumulation and provides a unique tool to track the homing-pathway of the stem cells. Results were confirmed by survival data for different groups with the Met+NSC treated group exhibiting increased survival trends.

This abstract and the presentation materials are available to members only; a login is required.

Join Here